Abstract: Provided herein are drug implants comprising a therapeutically active agent for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and a therapeutically active agent disposed therein. Additionally, provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may comprise bicalutamide, e.g., for use in the treatment of prostate cancer.

Abstract: The present invention is directed to virus-like particles (VLPs) which are engineered to present epitopes from Staphylococcus aureus (SA), preferably autoinducing peptides (AIPs) which regulate quorum-sensing dependent virulence in this pathogen, or epitopes from SA toxins and leukocidins. These VLPs may be used to provide immunogenic compositions and efficacious vaccines. In a mouse model of SA dermonecrosis, vaccination with AIP-containing VLPs or SA toxin-containing VLPs induces protective immunity to limit the pathogenesis of SA infection and promote bacterial clearance.

Abstract: The present invention is directed to the use of compounds which are modulators of the G protein-Coupled Estrogen Receptor (GPER) for the inhibition —and/or treatment of Bacterial infections, especially including metMctHin-resistant Staphylococcus aureus (MRSA) infections. Pharmaceutical compositions and methods of treatment of bacterial pathogens, including MRSA are also described.

Abstract: The present invention is directed to virus-like particles (VLPs) which are engineered to present epitopes from Staphylococcus aureus (SA), preferably autoinducing peptides (AIPs) which regulate quorum-sensing dependent virulence in this pathogen, or epitopes from SA toxins and leukocidins. These VLPs may be used to provide immunogenic compositions and efficacious vaccines. In a mouse model of SA dermonecrosis, vaccination with AIP-containing VLPs or SA toxin-containing VLPs induces protective immunity to limit the pathogenesis of SA infection and promote bacterial clearance.

Abstract: The present invention is directed to the use of compounds which are modulators of the G protein-Coupled Estrogen Receptor (GPER) for the inhibition—and/or treatment of Bacterial infections, especially including metMctHin-resistant Staphylococcus aureus (MRSA) infections. Pharmaceutical compositions and methods of treatment of bacterial pathogens, including MRSA are also described.

Abstract: Provided herein are compounds and compositions having antibiotic activity against methicillin resistant Staphylococcus aureus (MRSA). In particular, provided herein is a synbody that bactericidal against multiple strains of MRSA and that can be used in conjugation with currently approved ?-lactam antibiotics to treat MRSA strains having resistance to ?-lactam treatment. Also provided are methods of using the compounds and compositions for treating, preventing or reducing MRSA infections.

Abstract: In one aspect, this disclosure describes a pharmaceutical composition that generally includes frankiamicin A and a pharmaceutically acceptable carrier. In another aspect, this disclosure describes a method of treating a subject having, or at risk of having, a condition caused by a microbial infection treatable with frankiamicin A. Generally, the method includes administering to the subject an amount of frankiamicin A effective to ameliorate at least one symptom or clinical sign of the condition.

Abstract: In one aspect, this disclosure describes a pharmaceutical composition that generally includes frankiamicin A and a pharmaceutically acceptable carrier. In another aspect, this disclosure describes a method of treating a subject having, or at risk of having, a condition caused by a microbial infection treatable with frankiamicin A. Generally, the method includes administering to the subject an amount of frankiamicin A effective to ameliorate at least one symptom or clinical sign of the condition.

Abstract: Provided herein are compounds and compositions having antibiotic activity against methicillin resistant Staphylococcus aureus (MRSA). In particular, provided herein is a synbody that bactericidal against multiple strains of MRSA and that can be used in conjugation with currently approved ?-lactam antibiotics to treat MRSA strains having resistance to ?-lactam treatment. Also provided are methods of using the compounds and compositions for treating, preventing or reducing MRSA infections.

Abstract: This invention is an addition to a bib pouch; the bib has a pouch of absorbent fabric. To store cloth/like inside, to assist the care-giver to wipe away liquid or food that so often Run down the baby mouth when feeding, the inside of the pouch have an absorbent Fabric to keep the cloth/like dry-free inside of the pouch, the sides of the pouch as Velcro Strips to open a close the pouch, the top of pouch have zipper or Velcro Strips for easy access for the care-giver to asset the babies during feeding time, The bib pouch is also washable.

Abstract: A shopping cart attachment includes an advertisement and a calculator including a display. The calculator displays a message related to the advertisment on the display, in response to a predetermined occurrence such as depression of the CLEAR key. Because the calculator displays the advertising message, it is difficult for the shopper to ignore the advertisement. A freestanding pocket or desktop calculator may also display a message related to an advertisement on its case or housing, in response to a predetermined occurrence.